CN
Search Within
U0800000
应用筛选条件
关键词:'U0800000'
显示 1-30 共 89 条结果 关于 "U0800000" 范围 论文
Sheng-di Wu et al.
European journal of gastroenterology & hepatology, 24(11), 1247-1253 (2012-08-07)
The aim of this study was to evaluate the effects of ursodeoxycholic acid on patients with nonalcoholic steatohepatitis using meta-analysis. PubMed, EMBASE, Web of Science, Cochrane Library, Chinese Biomedical Databases, and article references were searched. We included randomized controlled trials
Sui Peng et al.
American journal of physiology. Gastrointestinal and liver physiology, 307(2), G129-G139 (2014-05-24)
Hydrophobic bile acids like deoxycholic acid (DCA), which cause oxidative DNA damage and activate NF-κB in Barrett's metaplasia, might contribute to carcinogenesis in Barrett's esophagus. We have explored mechanisms whereby ursodeoxycholic acid (UDCA, a hydrophilic bile acid) protects against DCA-induced
Ludovico Abenavoli et al.
Annals of hepatology, 12(1), 152-155 (2013-01-08)
Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed severe drug-induced hepatotoxicity during the
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
Heather Mortiboys et al.
Brain : a journal of neurology, 136(Pt 10), 3038-3050 (2013-09-04)
Previous drug screens aiming to identify disease-modifying compounds for Parkinson's disease have typically been based on toxin-induced in vitro and in vivo models of this neurodegenerative condition. All these compounds have failed to have a reliable disease-modifying effect in subsequent
V V Kollerov et al.
Steroids, 78(3), 370-378 (2013-01-22)
Selected actinobacteria and filamentous fungi of different taxonomy were screened for the ability to carry out regio- and stereospecific hydroxylation of lithocholic acid (LCA) at position 7β. The production of ursodeoxycholic acid (UDCA) was for the first time shown for
Nianbai Fang et al.
Experimental biology and medicine (Maywood, N.J.), 240(4), 488-497 (2014-10-12)
High-performance liquid chromatography (HPLC) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are generally accepted as the preferred techniques for detecting and quantitating analytes of interest in biological matrices on the basis of the rule that one chemical compound yields one LC-peak
[The use of hepatic protectors in clinical practice].
O N Minushkin et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 67-72 (2012-12-20)
Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis.
Yannick Bacq et al.
Gastroenterology, 143(6), 1492-1501 (2012-08-16)
We performed a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies born to women with intrahepatic cholestasis of pregnancy (ICP). We performed a systematic review of 9 published, randomized controlled
Patricia Martínez-Moya et al.
International immunopharmacology, 15(2), 372-380 (2012-12-19)
The denomination of inflammatory bowel disease comprises a group of chronic inflammatory diseases of the digestive tract, ulcerative colitis and Crohn's disease being the most important conditions. Bile acids may play a role both in etiology and pharmacology of this
L Serfaty et al.
Gastroenterologie clinique et biologique, 34(10), 516-522 (2010-07-09)
Colorectal cancer is respectively the third and second most common cancer among men and women in France. Interest in chemoprevention for colorectal cancer has increased over the last two decades. Beside non-steroidal anti-inflammatory drugs, ursodeoxycholic acid (UDCA) may have chemopreventive
Walee Chamulitrat et al.
Molecular pharmacology, 84(5), 696-709 (2013-08-27)
Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a hepatoprotectant in inhibiting apoptosis, inflammation, and hyperlipidemia in mouse models of nonalcoholic steatohepatitis (NASH). We studied the ability of UDCA-LPE to inhibit palmitate (Pal)-induced apoptosis in primary hepatocytes and delineate cytoprotective mechanisms. We showed that
Sara M Centuori et al.
Digestive diseases and sciences, 59(10), 2367-2380 (2014-07-17)
A high-fat diet coincides with increased levels of bile acids. This increase in bile acids, particularly deoxycholic acid (DCA), has been strongly associated with the development of colon cancer. Conversely, ursodeoxycholic acid (UDCA) may have chemopreventive properties. Although structurally similar
G Ia Khismatullina et al.
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, (4)(4), 60-65 (2013-02-14)
The therapeutic efficiency of ursosan in 64 overweight patients with chronic noncalculous cholecystitis and dysfunction of biliary tract was evaluated. Including of ursosan in the complex therapy of patients with chronic noncalculous cholecystitis enhances the efficiency of therapy, causes the
Qing Tang et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 15(9), 756-758 (2013-09-17)
To analyze the effects of ursodeoxycholic acid (UDCA) on the mRNA expression of multidrug resistance protein 3 (MDR3) and farnesoid X receptor (FXR) in infants with cholestatic hepatitis. Twenty-eight infants who were diagnosed with cholestatic hepatitis between July 2008 and
Jelena S Rudic et al.
The Cochrane database of systematic reviews, 12, CD000551-CD000551 (2012-12-14)
Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis. To assess
Riccardo Solimando et al.
Best practice & research. Clinical gastroenterology, 25(4-5), 555-568 (2011-11-30)
Chemoprevention of colorectal cancer has been an intense focus of research for many years. Among the possible candidate agents, ursodeoxycholic acid, folate, and hormone replacement therapy have been recently investigated with conflicting data. Experimental evidence shows that UDCA, folate and
Drug-induced vanishing bile duct syndrome: response to ursodiol.
C B O'Brien et al.
The American journal of gastroenterology, 91(7), 1456-1457 (1996-07-01)
Ursodeoxycholic and deoxycholic acids: A good and a bad bile acid for intestinal calcium absorption.
Valeria Rodríguez et al.
Archives of biochemistry and biophysics, 540(1-2), 19-25 (2013-10-08)
The aim of this study was to investigate the effect of ursodeoxycholic acid (UDCA) on intestinal Ca(2+) absorption and to find out whether the inhibition of this process caused by NaDOC could be prevented by UDCA. Chicks were employed and
Taiko Anzai et al.
Internal medicine (Tokyo, Japan), 52(3), 363-367 (2013-02-02)
A 42-year-old woman with hepatitis C virus-related cirrhosis underwent peginterferon alpha-2b therapy combined with ribavirin but could not achieve a sustained viral response. Following discontinuation of this combined therapy, the patient's serum transaminase levels suddenly became elevated. Therefore, the administration
Kenichi Harada et al.
Digestive diseases and sciences, 58(10), 3037-3043 (2013-06-15)
Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC
Nathalie Martin et al.
Molecular cancer, 13, 151-151 (2014-06-16)
Epidemiological data show that the incidence of carcinomas in humans is highly dependent on age. However, the initial steps of the age-related molecular oncogenic processes by which the switch towards the neoplastic state occurs remain poorly understood, mostly due to
C L Rosenbaum et al.
Drug intelligence & clinical pharmacy, 22(12), 941-945 (1988-12-01)
Ursodiol, a naturally occurring bile acid, has gained Food and Drug Administration approval for the dissolution of cholesterol gallstones. Ursodiol inhibits hepatic cholesterol synthesis and secretion. Lithocholic acid, a potentially hepatotoxic metabolite of ursodiol and chenodiol, may accumulate to a
Katharine Cheng et al.
The Cochrane database of systematic reviews, 12(12), CD000222-CD000222 (2014-12-17)
Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of cystic fibrosis-related liver disease. This condition peaks in adolescence
F J Reen et al.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 33(10), 1763-1771 (2014-05-13)
Chronic respiratory infections are a leading global cause of morbidity and mortality. However, the molecular triggers that cause respiratory pathogens to adopt persistent and often untreatable lifestyles during infection remain largely uncharacterised. Recently, bile aspiration caused by gastro-oesophageal reflux (GOR)
Zun Xiang et al.
BMC gastroenterology, 13, 140-140 (2013-09-24)
Non-alcoholic steatohepatitis (NASH) is a condition that occurs during the progression of non-alcoholic fatty liver disease. Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Western
Michael D Jones et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 966, 200-207 (2014-05-13)
Ultra high resolution SFC-MS (on sub-2μm particles) coupled to mass spectrometry has been evaluated for the metabolic profiling of rat and dog bile. The selectivity of the SFC separation differed from that seen in previous reversed-phase UPLC-MS studies on bile
Ursodiol: good drug makes good.
Teresa A Brentnall
Gastroenterology, 124(4), 1139-1140 (2003-04-03)
Susana Solá et al.
Current issues in molecular biology, 9(2), 123-138 (2007-05-11)
Apoptosis represents a universal and exquisitely efficient cellular suicide pathway essential for a variety of normal biological processes ranging from embryonic development to ageing. In fact, tissue homeostasis is dependent on the perfect balance between positive and negative signals that
Valerie A San Luis et al.
The Annals of pharmacotherapy, 41(11), 1867-1872 (2007-10-04)
To review the role of ursodeoxycholic acid (ursodiol) in treating parenteral nutrition-associated cholestasis (PNAC). A MEDLINE (1950-May 2007) search was performed using the key terms parenteral nutrition, cholestasis, ursodeoxycholic acid, and ursodiol. All English-language articles that evaluated the safety and
1/3